Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: Evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects

Brain Research Bulletin

Volumn 93, Issue , 2013, Pages 32-38

  Vizi, E S ^a,b   Kisfali, M ^a   Lorincz, T ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Excitotoxicity; Extrasynaptic receptors; GluN2A; GluN2B; Neuroprotection; Nonsynaptic ionotropic receptors

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; BESONPRODIL; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIZOCILPINE; FLUOXETINE; IFENPRODIL; MEMANTINE; MK 0657; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEU 2000; RADIPRODIL; RG 1103; RG 13579; TRAXOPRODIL; UNCLASSIFIED DRUG;

CALCIUM CELL LEVEL; CELL DESTRUCTION; CELL SURVIVAL; EXCITOTOXICITY; GENE EXPRESSION; HUMAN; LONG TERM POTENTIATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS;

ANIMALS; BRAIN INJURIES; CALCIUM; FLUOXETINE; HUMANS; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES;

EID: 84875618557     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.10.005     Document Type: Review

References (107)

1. Abe T., Matsumura S., et al. Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain. The European Journal of Neuroscience 2005, 22(6):1445-1454.
2. Acler M., Robol E., et al. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. Journal of Neurology 2009, 256(7):1152-1158.
3. Adam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxidants and Redox Signaling 2005, 7(9-10):1140-1149.
4. Addy C., Assaid C., et al. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. Journal of Clinical Pharmacology 2009, 49(7):856-864.
5. Balsara R., Li N., et al. Opposing action of conantokin-G on synaptically and extrasynaptically-activated NMDA receptors. Neuropharmacology 2012, 62(7):2227-2238.
6. Bayer K.U., LeBel E., et al. Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2006, 26(4):1164-1174.
7. Beique J.C., Huganir R.L. AMPA receptor subunits get their share of the pie. Neuron 2009, 62(2):165-168.
8. Bellone C., Nicoll R.A. Rapid bidirectional switching of synaptic NMDA receptors. Neuron 2007, 55(5):779-785.
9. Benveniste H., Drejer J., et al. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. Journal of Neurochemistry 1984, 43(5):1369-1374.
10. Berberich S., Punnakkal P., et al. Lack of NMDA receptor subtype selectivity for hippocampal long-term potentiation. The Journal of Neuroscience 2005, 25(29):6907-6910.
11. Besret L., Debruyne D., et al. A comprehensive investigation of plasma and brain regional pharmacokinetics of imipramine and its metabolites during and after chronic administration in the rat. Journal of Pharmaceutical Sciences 1996, 85(3):291-295.
12. Bolo N.R., Hode Y., et al. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000, 23(4):428-438.
13. Borgdorff A.J., Choquet D. Regulation of AMPA receptor lateral movements. Nature 2002, 417(6889):649-653.
14. Bresink I., Benke T.A., et al. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. British Journal of Pharmacology 1996, 119(2):195-204.
15. Bullock R., Kuroda Y., et al. Prevention of post-traumatic excitotoxic brain damage with NMDA antagonist drugs: a new strategy for the nineties. Acta Neurochirurgica. Supplementum 1992, 55:49-55.
16. Cao H., Ren W.H., et al. Activation of glycine site and GluN2B subunit of NMDA receptors is necessary for ERK/CREB signaling cascade in rostral anterior cingulate cortex in rats: implications for affective pain. Neuroscience Bulletin 2012, 28(1):77-87.
17. Castren E. Is mood chemistry? Nature reviews. Neuroscience 2005, 6(3):241-246.
18. Castren E., Voikar V., et al. Role of neurotrophic factors in depression. Current Opinion in Pharmacology 2007, 7(1):18-21.
19. Chang Y.C., Tzeng S.F., et al. Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups. Neurobiology of Disease 2006, 24(1):101-113.
20. Cho S.I., Park U.J., et al. Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News and Perspectives 2010, 23(9):549-556.
21. Chollet F., Tardy J., et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurology 2011, 10(2):123-130.
22. Czöndör K., Mondin M., et al. Unified quantitative model of AMPA receptor trafficking at synapses. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(9):3522-3527.
23. Dam M., Tonin P., et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke: A Journal of Cerebral Circulation 1996, 27(7):1211-1214.
24. Ellison G. The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain research. Brain Research Reviews 1995, 20(2):250-267.
25. Farinelli M., Heitz F.D., et al. Selective regulation of NR2B by protein phosphatase-1 for the control of the NMDA receptor in neuroprotection. PLoS One 2012, 7(3):e34047.
26. Favaron M., Manev H., et al. Down-regulation of protein kinase C protects cerebellar granule neurons in primary culture from glutamate-induced neuronal death. Proceedings of the National Academy of Sciences of the United States of America 1990, 87(5):1983-1987.
27. Fellin T., Pascual O., et al. Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. Neuron 2004, 43(5):729-743.
28. Fischer G., Mutel V., et al. Ro 25-6981, a highly potent and selective blocker of N-methyl-d-aspartate receptors containing the NR2B subunit. Characterization in vitro. The Journal of Pharmacology and Experimental Therapeutics 1997, 283(3):1285-1292.
29. Franco R., Panayiotidis M.I., et al. Autocrine signaling involved in cell volume regulation: the role of released transmitters and plasma membrane receptors. Journal of Cellular Physiology 2008, 216(1):14-28.
30. Fuchs S.A., Peeters-Scholte C.M., et al. Increased concentrations of both NMDA receptor co-agonists d-serine and glycine in global ischemia: a potential novel treatment target for perinatal asphyxia. Amino Acids 2012, 43(1):355-363.
31. Gogas K.R. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Current Opinion in Pharmacology 2006, 6(1):68-74.
32. Gowd K.H., Han T.S., et al. Conantokins derived from the Asprella clade impart conRl-B, an N-methyl d-aspartate receptor antagonist with a unique selectivity profile for NR2B subunits. Biochemistry 2012, 51(23):4685-4692.
33. Gwag B.J., Lee Y.A., et al. Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2007, 27(6):1142-1151.
34. Hardingham G.E., Fukunaga Y., et al. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature Neuroscience 2002, 5(5):405-414.
35. Henneberger C., Papouin T., et al. Long-term potentiation depends on release of d-serine from astrocytes. Nature 2010, 463(7278):232-236.
36. Hong C.J., Liou Y.J., et al. Effects of BDNF polymorphisms on brain function and behavior in health and disease. Brain Research Bulletin 2011, 86(5-6):287-297.
37. Horsfield S.A., Rosse R.B., et al. Fluoxetine's effects on cognitive performance in patients with traumatic brain injury. International Journal of Psychiatry in Medicine 2002, 32(4):337-344.
38. Ibrahim L., Diaz Granados N., et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychopharmacology 2012, 32(4):551-557.
39. Jung S.C., Eun S.Y., et al. Kv4.2 block of long-term potentiation is partially dependent on synaptic NMDA receptor remodeling. Brain Research Bulletin 2011, 84(1):17-21.
40. Katayama Y., Becker D.P., et al. Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. Journal of Neurosurgery 1990, 73(6):889-900.
41. Kiedrowski L., Wroblewski J.T., et al. Intracellular sodium concentration in cultured cerebellar granule cells challenged with glutamate. Molecular Pharmacology 1994, 45(5):1050-1054.
42. Kim do H., Li H., et al. Effects of fluoxetine on ischemic cells and expressions in BDNF and some antioxidants in the gerbil hippocampal CA1 region induced by transient ischemia. Experimental Neurology 2007, 204(2):748-758.
43. Kiss J.P. Theory of active antidepressants: a nonsynaptic approach to the treatment of depression. Neurochemistry International 2008, 52(1-2):34-39.
44. Kiss J.P., Szasz B.K., et al. GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine. Neurochemistry International 2012, 60(2):170-176.
45. Kopach O., Kao S.C., et al. Inflammation alters trafficking of extrasynaptic AMPA receptors in tonically firing lamina II neurons of the rat spinal dorsal horn. Pain 2011, 152(4):912-923.
46. Krystal J.H., Tolin D.F., et al. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14(13-14):690-697.
47. Lei Z., Deng P., et al. Downregulation of Kv4.2 channels mediated by NR2B-containing NMDA receptors in cultured hippocampal neurons. Neuroscience 2010, 165(2):350-362.
48. Lendvai B., Vizi E.S. Nonsynaptic chemical transmission through nicotinic acetylcholine receptors. Physiological Reviews 2008, 88(2):333-349.
49. Léveillé F., El Gaamouch F., et al. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2008, 22(12):4258-4271.
50. Lim C.M., Kim S.W., et al. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Journal of Neuroscience Research 2009, 87(4):1037-1045.
51. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nature reviews. Drug Discovery 2006, 5(2):160-170.
52. Liu L., Wong T.P., et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 2004, 304(5673):1021-1024.
53. Liu S.B., Zhang N., et al. G-protein-coupled receptor 30 mediates rapid neuroprotective effects of estrogen via depression of NR2B-containing NMDA receptors. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2012, 32(14):4887-4900.
54. Liu Y., Wong T.P., et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. Journal of Neuroscience 2007, 27(11):2846-2857.
55. Lu W., Shi Y., et al. Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach. Neuron 2009, 62(2):254-268.
56. MacDermott A.B., Role L.W., et al. Presynaptic ionotropic receptors and the control of transmitter release. Annual Review of Neuroscience 1999, 22:443-485.
57. Malenka R.C., Nicoll R.A. NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends in Neurosciences 1993, 16(12):521-527.
58. Mangialasche F., Solomon A., et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurology 2010, 9(7):702-716.
59. Manji H.K., Quiroz J.A., et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biological Psychiatry 2003, 53(8):707-742.
60. Martel M.A., Wyllie D.J., et al. In developing hippocampal neurons, NR2B-containing N-methyl-d-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience 2009, 158(1):334-343.
61. Massey P.V., Johnson B.E., et al. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2004, 24(36):7821-7828.
62. Masugi-Tokita M., Shigemoto R. High-resolution quantitative visualization of glutamate and GABA receptors at central synapses. Current Opinion in Neurobiology 2007, 17(3):387-393.
63. Maya Vetencourt J.F., Sale A., et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008, 320(5874):385-388.
64. Mills L.R., Kater S.B. Neuron-specific and state-specific differences in calcium homeostasis regulate the generation and degeneration of neuronal architecture. Neuron 1990, 4(1):149-163.
65. Milusheva E., Doda M., et al. Regulatory interactions among axon terminals affecting the release of different transmitters from rat striatal slices under hypoxic and hypoglycemic conditions. Journal of Neurochemistry 1992, 59(3):946-952.
66. Milusheva E., Sperlagh B., et al. Non-synaptic release of [3H]noradrenaline in response to oxidative stress combined with mitochondrial dysfunction in rat hippocampal slices. Neuroscience 2003, 120(3):771-781.
67. Mony L., Kew J.N., et al. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. British Journal of Pharmacology 2009, 157(8):1301-1317.
68. Nagy J. The NR2B subtype of NMDA receptor: a potential target for the treatment of alcohol dependence. Current drug targets. CNS and Neurological Disorders 2004, 3(3):169-179.
69. Nagy J., Boros A., et al. Inducible expression and pharmacology of recombinant NMDA receptors, composed of rat NR1a/NR2B subunits. Neurochemistry International 2003, 43(1):19-29.
70. Nagy J., Horvath C., et al. NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurones. Neurochemistry International 2004, 44(1):17-23.
71. Newpher T.M., Ehlers M.D. Glutamate receptor dynamics in dendritic microdomains. Neuron 2008, 58(4):472-497.
72. Orellana J.A., von Bernhardi R., et al. Glial hemichannels and their involvement in aging and neurodegenerative diseases. Reviews in the Neurosciences 2012, 23(2):163-177.
73. Papouin T., Ladepeche L., et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150(3):633-646.
74. Pariente J., Loubinoux I., et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Annals of Neurology 2001, 50(6):718-729.
75. Parsons C.G., Stoffler A., et al. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007, 53(6):699-723.
76. Perez E.L., Lauritzen F., et al. Evidence for astrocytes as a potential source of the glutamate excess in temporal lobe epilepsy. Neurobiology of Disease 2012, 47(3):331-337.
77. Poleszak E., Wlaz P., et al. A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. Journal of Neural Transmission 2011, 118(11):1535-1546.
78. Ramoa A.S., Alkondon M., et al. The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. Journal of Pharmacology and Experimental Therapeutics 1990, 254(1):71-82.
79. Raveendran R., Devi Suma Priya S., et al. Phosphorylation status of the NR2B subunit of NMDA receptor regulates its interaction with calcium/calmodulin-dependent protein kinase II. Journal of Neurochemistry 2009, 110(1):92-105.
80. Rossi D.J., Oshima T., et al. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 2000, 403(6767):316-321.
81. Salomone S., Caraci F., et al. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British Journal of Clinical Pharmacology 2012, 73(4):504-517.
82. Sattler R., Xiong Z., et al. Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2000, 20(1):22-33.
83. Snell L.D., Johnson K.M. Effects of nicotinic agonists and antagonists on N-methyl-d-aspartate-induced 3H-norepinephrine release and 3H-(1-[1-(2-thienyl)cyclohexyl]-piperidine) binding in rat hippocampus. Synapse 1989, 3(2):129-135.
84. 2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochemical and Biophysical Research Communications 1991, 181(3):968-975.
85. Sykova E., Vargova L. Extrasynaptic transmission and the diffusion parameters of the extracellular space. Neurochemistry International 2008, 52(1-2):5-13.
86. Szasz B.K., Mike A., et al. Direct inhibitory effect of fluoxetine on N-methyl-d-aspartate receptors in the central nervous system. Biological Psychiatry 2007, 62(11):1303-1309.
87. Szatkowski M., Barbour B., et al. Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake. Nature 1990, 348(6300):443-446.
88. Tang Y.P., Shimizu E., et al. Genetic enhancement of learning and memory in mice. Nature 1999, 401(6748):63-69.
89. Thomas C.G., Miller A.J., et al. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. Journal of Neurophysiology 2006, 95(3):1727-1734.
90. Tovar K.R., Westbrook G.L. Mobile NMDA receptors at hippocampal synapses. Neuron 2002, 34(2):255-264.
91. + channel block prevents the ischemia-induced release of norepinephrine from spinal cord slices. European Journal of Pharmacology 1998, 346(2-3):145-150.
92. 2+-permeable AMPA and reduced NR2B NMDA receptor-mediated neurotransmission at dorsal horn nociceptive synapses during inflammatory pain in the rat. The Journal of Physiology 2008, 586(2):515-527.
93. Vizi E.S. Presynaptic modulation of neurochemical transmission. Progress in Neurobiology 1979, 12(3-4):181-290.
94. Vizi E.S. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacological Reviews 2000, 52(1):63-89.
95. Vizi E.S., Fekete A., et al. Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment. British Journal of Pharmacology 2010, 160(4):785-809.
96. Vizi E.S., Labos E. Non-synaptic interactions at presynaptic level. Progress in Neurobiology 1991, 37(2):145-163.
97. Vizi E.S., Lendvai B. Modulatory role of presynaptic nicotinic receptors in synaptic and non-synaptic chemical communication in the central nervous system. Brain Research. Brain Research Reviews 1999, 30(3):219-235.
98. Wahl A.S., Buchthal B., et al. Hypoxic/ischemic conditions induce expression of the putative pro-death gene Clca1 via activation of extrasynaptic N-methyl-d-aspartate receptors. Neuroscience 2009, 158(1):344-352.
99. Williams K. Ifenprodil discriminates subtypes of the N-methyl-d-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Molecular Pharmacology 1993, 44(4):851-859.
100. Wu H.M., Tzeng N.S., et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2009, 34(10):2344-2357.
101. Yamamoto S., Morinobu S., et al. Alterations in the hippocampal glycinergic system in an animal model of posttraumatic stress disorder. Journal of Psychiatric Research 2010, 44(15):1069-1074.
102. Yang Q., Liao Z.H., et al. Hippocampal synaptic metaplasticity requires the activation of NR2B-containing NMDA receptors. Brain Research Bulletin 2011, 84(2):137-143.
103. Yang Y., Ge W., et al. Contribution of astrocytes to hippocampal long-term potentiation through release of d-serine. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(25):15194-15199.
104. Zheng Y., Cui S., et al. Dexmedetomidine prevents remifentanil-induced postoperative hyperalgesia and decreases spinal tyrosine phosphorylation of N-methyl-d-aspartate receptor 2B subunit. Brain Research Bulletin 2012, 87(4-5):427-431.
105. Zhou M., Baudry M. Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. Journal of Neuroscience 2006, 26(11):2956-2963.
106. Zhou M., Baudry M. Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. The Journal of Neuroscience: The Official journal of the Society for Neuroscience 2006, 26(11):2956-2963.
107. Zittel S., Weiller C., et al. Citalopram improves dexterity in chronic stroke patients. Neurorehabilitation and Neural Repair 2008, 22(3):311-314.